Discovery
Identifying novel targets through deep biological insights into brain function and dysfunction.
Pipeline
Translating ion channel science into meaningful medicines
With deep expertise in ion channel biology, we are advancing a differentiated pipeline led by our late-stage investigational candidate, which is being studied in multiple Phase 3 trials in epilepsy, major depressive disorder (MDD), and bipolar depression (BPD). Our early-stage pipeline features Kv7 potassium channel openers and Nav sodium channel modulators being advanced for select high-need indications.
Preclinical Development
Robust pharmacology, toxicology, and proof-of-concept studies to ensure strong translational potential.
Our approach in epilepsy
We are developing a novel, potent Kv7 potassium channel opener which is in
Phase 3 Our Focus for the treatment of focal and generalized seizures. If
approved, it would be the only potassium channel opener among antiseizure
medications.
We are also exploring the Kv7 potassium channel as a key regulator of neuronal
excitability that may play a role in both epilepsy and depression, which is
increasingly being recognized as a neuronal circuit disorder.
Contact Us
Our approach in pain
We have extensive history researching the sodium channel Nav1.7 as a novel pain target, both through multiple industry collaborations and our own discovery research. This history started more than 10 years ago with the identification of a loss of function in the sodium channel Nav1.7 as the cause of congenital indifference to pain (CIP), an extremely rare autosomal recessive disorder whose carriers are unable to feel pain but are otherwise healthy. Since then, we have focused on optimizing chemistry to address the limitations of earlier drug candidates targeting Nav1.7 and believe we are now on the precipice of realizing the potential of this promising pain target with our clinical program, which is being investigated in a Phase 1 study.
Contact Us
